Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18054896 | 0.91 | MEN1 (0.54) | HDAC4EPHX1MEN1KMT2ANPC1 | |
| SCHEMBL3320567 | 0.85 | RAB9A (0.68) | MAPK1OPRK1CDK2AP1CHEK1HDAC4 | |
| SCHEMBL14023410 | 0.85 | CHEK1 (0.57) | MAPK1OPRK1CDK2AP1CHEK1HDAC4 | |
| SCHEMBL17888469 | 0.85 | RAB9A (0.68) | MAPK1OPRK1CDK2AP1CHEK1HDAC4 | |
| SCHEMBL28280152 | 0.85 | MAPK1 (0.59) | MAPK1OPRK1CDK2AP1CHEK1HDAC4 | |
| SCHEMBL1163022 | 0.85 | MAPK1 (0.59) | MAPK1OPRK1CDK2AP1CHEK1HDAC4 | |
| SCHEMBL1163023 | 0.85 | MAPK1 (0.59) | MAPK1OPRK1CDK2AP1CHEK1HDAC4 | |
| SCHEMBL13883877 | 0.85 | MAPK1 (0.56) | MAPK1OPRK1CHEK1HDAC4PBK | |
| Hydrochloric Acid SCHEMBL4082980 | 0.83 | MAPK1 (0.55) | MAPK1OPRK1CHEK1HDAC4PBK | |
| SCHEMBL12045094 | 0.83 | MAPK1 (0.57) | MAPK1OPRK1CDK2AP1CHEK1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215150-B1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-07-20 | — | — | EP | disclosed |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3215150-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | The Regents of The University of Michigan (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| WO-2016073847-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073847-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2123769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | Kaneka Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | MAPK1 1245/4885OPRK1 2572/4885CDK2AP1 968/4885 |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | SREBF1, SREBF2, BPTF | MAPK1 1245/4885OPRK1 2572/4885CDK2AP1 968/4885 |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | MAPK1 3426/4885OPRK1 1278/4885CDK2AP1 4193/4885 |
| US-20100105917-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | MAPK1 3426/4885OPRK1 1278/4885CDK2AP1 4193/4885 |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | MAPK1 3426/4885OPRK1 1278/4885CDK2AP1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.